China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China
· Delayed Price · Currency is CNY 17.72
+0.15 (0.85%)
Apr 29, 2026, 3:04 PM CST
SHE:300294 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 1,843 | 2,058 | 1,734 | 2,651 | 2,761 | 2,645 | Upgrade
|
| Other Revenue | 0.99 | 0.99 | 0.79 | 0.85 | -2.22 | 5.21 | Upgrade
|
| Revenue | 1,844 | 2,059 | 1,735 | 2,652 | 2,759 | 2,651 | Upgrade
|
| Revenue Growth (YoY) | 1.21% | 18.69% | -34.58% | -3.87% | 4.08% | 5.47% | Upgrade
|
| Cost of Revenue | 968.48 | 1,043 | 615.97 | 1,259 | 1,255 | 1,187 | Upgrade
|
| Gross Profit | 875.86 | 1,016 | 1,119 | 1,393 | 1,504 | 1,463 | Upgrade
|
| Selling, General & Admin | 622.92 | 648.36 | 603.65 | 774.85 | 923.64 | 969.52 | Upgrade
|
| Research & Development | 48.22 | 54.55 | 66.89 | 67.7 | 49.58 | 59.29 | Upgrade
|
| Other Operating Expenses | 35.27 | 18.23 | 17.47 | 18.98 | 20.83 | 19.99 | Upgrade
|
| Operating Expenses | 721.87 | 742.66 | 696.81 | 863.9 | 996.86 | 1,049 | Upgrade
|
| Operating Income | 153.99 | 272.95 | 422.12 | 529.38 | 507.16 | 414.49 | Upgrade
|
| Interest Expense | -1.7 | -1.16 | -0.66 | -0.46 | -0.62 | -10.53 | Upgrade
|
| Interest & Investment Income | 39.57 | 37.42 | 42.49 | 45.31 | 64.93 | 63.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.61 | 6.61 | -2.77 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 3.61 | -2.54 | 0.87 | -0.43 | 4.02 | -8.3 | Upgrade
|
| EBT Excluding Unusual Items | 202.09 | 313.28 | 462.05 | 573.81 | 575.49 | 459.57 | Upgrade
|
| Impairment of Goodwill | -110.47 | -110.47 | -72.61 | -298.41 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 41.97 | 59.98 | 65.58 | 85.74 | - | 10.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.73 | 5.1 | -0.61 | 1.3 | 0.07 | -0.87 | Upgrade
|
| Asset Writedown | -199.04 | -199.11 | -11.18 | -28.31 | -51.03 | -36.37 | Upgrade
|
| Other Unusual Items | 37.25 | 35.1 | 34.49 | 19.59 | 7.47 | 10.08 | Upgrade
|
| Pretax Income | -23.47 | 103.88 | 477.71 | 353.71 | 532 | 443.12 | Upgrade
|
| Income Tax Expense | -26.85 | -8.76 | 81.19 | 105.56 | 86.51 | 84.84 | Upgrade
|
| Earnings From Continuing Operations | 3.38 | 112.64 | 396.53 | 248.15 | 445.49 | 358.28 | Upgrade
|
| Minority Interest in Earnings | 0.05 | 0.06 | 0.46 | -10.68 | -13.29 | -13.75 | Upgrade
|
| Net Income | 3.44 | 112.7 | 396.99 | 237.47 | 432.2 | 344.53 | Upgrade
|
| Net Income to Common | 3.44 | 112.7 | 396.99 | 237.47 | 432.2 | 344.53 | Upgrade
|
| Net Income Growth | -99.11% | -71.61% | 67.18% | -45.06% | 25.45% | 32.48% | Upgrade
|
| Shares Outstanding (Basic) | 514 | 512 | 503 | 505 | 503 | 436 | Upgrade
|
| Shares Outstanding (Diluted) | 514 | 512 | 503 | 505 | 503 | 436 | Upgrade
|
| Shares Change (YoY) | 2.65% | 1.94% | -0.54% | 0.53% | 15.24% | 2.30% | Upgrade
|
| EPS (Basic) | 0.01 | 0.22 | 0.79 | 0.47 | 0.86 | 0.79 | Upgrade
|
| EPS (Diluted) | 0.01 | 0.22 | 0.79 | 0.47 | 0.86 | 0.79 | Upgrade
|
| EPS Growth | -99.13% | -72.15% | 68.08% | -45.35% | 8.86% | 29.51% | Upgrade
|
| Free Cash Flow | -627.32 | -474.15 | 101.99 | 554.23 | 458.03 | 1,277 | Upgrade
|
| Free Cash Flow Per Share | -1.22 | -0.93 | 0.20 | 1.10 | 0.91 | 2.93 | Upgrade
|
| Dividend Per Share | 0.223 | 0.223 | 0.320 | 0.300 | 0.200 | 0.150 | Upgrade
|
| Dividend Growth | -30.31% | -30.31% | 6.67% | 50.00% | 33.33% | 130.77% | Upgrade
|
| Gross Margin | 47.49% | 49.32% | 64.50% | 52.54% | 54.52% | 55.21% | Upgrade
|
| Operating Margin | 8.35% | 13.26% | 24.33% | 19.96% | 18.38% | 15.64% | Upgrade
|
| Profit Margin | 0.19% | 5.47% | 22.88% | 8.95% | 15.67% | 13.00% | Upgrade
|
| Free Cash Flow Margin | -34.01% | -23.03% | 5.88% | 20.90% | 16.60% | 48.19% | Upgrade
|
| EBITDA | 307.62 | 415.82 | 521.95 | 624.38 | 600.38 | 510.65 | Upgrade
|
| EBITDA Margin | 16.68% | 20.19% | 30.09% | 23.54% | 21.76% | 19.27% | Upgrade
|
| D&A For EBITDA | 153.63 | 142.87 | 99.82 | 94.99 | 93.22 | 96.16 | Upgrade
|
| EBIT | 153.99 | 272.95 | 422.12 | 529.38 | 507.16 | 414.49 | Upgrade
|
| EBIT Margin | 8.35% | 13.26% | 24.33% | 19.96% | 18.38% | 15.64% | Upgrade
|
| Effective Tax Rate | - | - | 16.99% | 29.84% | 16.26% | 19.15% | Upgrade
|
| Revenue as Reported | 1,844 | 2,059 | 1,735 | 2,652 | 2,759 | 2,651 | Upgrade
|
| Advertising Expenses | - | 4.55 | 3.26 | 2.73 | 1.82 | 2.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.